Nikolaos E Tzanakis, Department of Social Medicine & Thoracic Medicine, Medical School University of Crete, Crete 71110, Greece

Ioanna G Tsiligianni, General Practitioner, Agia Barvara Health Care Center, Heraklion, Crete 70003, Greece

Nikolaos M Siafakas, Department of Thoracic Medicine, Medical School University of Crete, Crete 71110, Greece

Author contributions: Tzanakis NE designed the study; Tzanakis NE and Tsiligianni IG performed the search strategy for identification of studies and wrote the article; Siafakas NM reviewed the article and gave relevant suggestions.

Correspondence to: Ioanna G Tsiligianni, MD, PhD, MPH, General Practitioner, Agia Barbara Health Care Centre, Heraklion, Crete 70003, Greece. pdkapa@yahoo.gr

Telephone: +30-2810-392855   Fax: +30-2810-542650

Received: September 3, 2009   Revised: December 3, 2009

Accepted: December 10, 2009

Published online: January 21, 2010

Abstract

Inflammatory bowel disease (IBD) has been asso­ciated with either clinical or subclinical airway and parenchymal lung involvement and interstitial lung complications. Several studies have reported that atopy has a high prevalence in IBD patients. Overlapping allergic disorders seem to be present in both the respiratory and gastrointestinal systems. The purpose of this review is to update clinicians on recent available literature and to discuss the need for a highly suspicious approach by clinicians.

© 2010 Baishideng. All rights reserved.

Key words: Atopy; Inflammatory bowel disease; Pul­monary involvement

Peer reviewers: Dr. Zoran Krivokapic, Professor, MD, FRCS, Institute for Digestive Disease, First Surgical Clinic, Clinical Center of Serbia, 6, Dr Koste Todorovica, Belgrade, 11000, Serbia; Javier Martin, MD, PhD, Department of Immunology, Institute of Parasitology and Biomedicine López-Neyra, P.T. Health Sciences, Avd del Conocimiento s/n, 18100, Armilla, Granada, Spain

Tzanakis NE, Tsiligianni IG, Siafakas NM. Pulmonary involve­ment and allergic disorders in inflammatory bowel disease. World J Gastroenterol 2010; 16(3): 299-305  Available from: URL: http://www.wjgnet.com/1007-9327/full/v16/i3/299.htm  DOI: http://dx.doi.org/10.3748/wjg.v16.i3.299

INTRODUCTION

Ulcerative colitis (UC) and Crohn’s disease (CD) are the two major forms of chronic relapsing inflammatory bowel disease (IBD). Apart from overlapping epide­miological, clinical, radiological, endoscopic and histo­logical characteristics^[1,2] between UC and CD, there are clear differences in the extent of inflammation in the gastrointestinal tract and in several immunological parameters^[3-5] suggesting that they are distinct disease processes. The pathogenesis of IBD seems to be more complex than one single cause and probably involves an interaction between genetic predisposing factors^[6-8], exogenous and endogenous triggers^[3,9-14], and modifying factors^[3,15,16]. The outcome of these interactions is a spontaneously relapsing and remitting inflammatory process in intestinal mucosa associated with recruitment and activation of lymphocytes, macrophages and other inflammatory cells^[3,17-20].

    Extraintestinal and systemic manifestations occur frequently in patients with IBD^[20-25]. These various disease states can be diagnosed before, concomitant with, or after the diagnosis of a specific type of IBD. Two large case studies have demonstrated that between 25% and 36% of patients with either type of idiopathic IBD will have at least one such associated disease^[22-23]. Yamamoto-Furusho et al^[8] found that extraintestinal manifestations were present in 41.5% of 848 cases with UC. More than 100 systemic complications involving almost every organ system in the body have been described^[26]. The spectrum, the frequency and the temporal relation of the complications have led to the hypothesis that IBD is a systemic disorder^[22-23,26].

    IBD is associated with a wide variety of extraintestinal lesions in many organs and over some decades the pattern has changed and the lung is regarded as one of these affected organs^[21,26-31]. In recent years a few hundred cases with pulmonary involvement and IBD have been reported and in that way pulmonary involvement has been proved to be common. A growing number of studies in the literature have reported either clinical or latent pulmonary involvement in patients with IBD^[29,31-34]. In this review we will focus on the extraintestinal manifestations that are associated with lungs and airways. In an attempt to classify the reported lung manifestations in patients with IBD in a more useful way, the manifestations were distinguished as follows: (1) involvement of airways; (2) pulmonary function testing abnormalities; and (3) diffuse or localized interstitial lung complications caused by either disease or treatment received. Finally, studies regarding the relationship between allergy and IBD will be discussed in detail.

IBD AND AIRWAYS

The manifestations of IBD in airways include, chronic bronchial suppuration particularly in patients with UC^[31,34-36], bronchiectasis^[32,37-40], localized obstruction of upper airways^[41], bronchiolitis obliterans organizing pneumonia^[32,42,43], granulomatous bronchiolitis^[44], trache­obronchitis^[45,46], bronchiolitis obliterans^[47], tracheo­bronchial stenosis^[48] and diffuse obstructive disease^[34,49]. Obstructive disease was not confirmed in some studies^[50]. An increased risk of both UC and CD in chronic obstructive pulmonary disease (COPD) patients has been reported in some studies, focusing attention on the association between airway diseases (AD) and IBD^[51]. We have reported a small airway dysfunction, detected by density dependence methods, in patients with IBD^[52]. In the study by Louis et al^[53], patients with IBD, free of pulmonary symptoms, independently of the presence of atopy, showed bronchial hyperresponsiveness. This interesting finding could lead to the hypothesis that local mucosal inflammation in the intestine is responsible for the mild airway inflammation and not atopy. This hypothesis is not new. Basal cell hyperplasia, membrane thickening and submucosal inflammation have been reported in patients with UC and bronchial suppuration^[36]. CD may affect the oral cavity and the colon^[26,54,55] while both UC^[34,41] and CD^[56] have been reported to involve the larynx. There are also some morphological and developmental similarities between colonic and bronchial epithelium. Both are derived from the primitive gut, whereas the lungs arise from the laryngo-tracheal bud. Both are composed of columnar epithelium with goblet cells and submucosal mucous glands. Furthermore, there is increasing evidence that an immune system specific to the gastrointestinal tract common to all mucosal surfaces exists^[57], in which lymphocytes are sensitized to antigens at one mucosal site and by circulation are localized and produce inflammation in other mucosal surfaces^[53,58-61].

PULMONARY FUNCTION TESTING ABNORMALITIES

Previous reports concerning pulmonary function abnor­malities in patients with IBD are conflicting. In some studies no differences in pulmonary function tests (PFTs) between patients with IBD and the control group were found^[49,62]. In the study by Neilly et al^[49] airway obstruction was the most common finding affecting patients with CD (45%). However, the indices of airway obstruction were not significantly different from those obtained in age-, sex- and smoking-matched controls. As discussed above, Louis et al^[53] reported an increased bronchial responsiveness in IBD patients, while the baseline lung function tests were within the normal range. In the study by Mohamed-Hussein et al^[63], fifteen out of 26 patients with UC had an important impairment in PFTs. In the study by Herrlinger et al^[64], the impairment in PFTs was more pronounced in IBD patients with active disease than in those with inactive disease.

    Pulmonary diffusion capacity (TLCO) is often impaired in IBD patients. Heatley et al^[65] found an increased prevalence of TLCO impairment in 25% of patients with CD. Reduction of TLCO in patients with IBD has been reported in various studies^{[61,64,66-69]}. Eade et al^[66] and Bonniere et al^[59] found that the reduced TLCO or other PFTs parameters were not correlated with the location and severity of IBD or with the concurrent medication mode^[59,66]. We examined 132 patients, 47 (17 female, 30 male) with CD and 85 (35 female, 50 male) mean age 40 years with UC. The main finding of our study was a high prevalence of impaired TLCO in patients with CD and UC suggesting involvement of the lung parenchyma^[70]. All other PFTs parameters were abnormal in a high percentage of patients, however, they did not show statistically significant differences from those in the control group. Our data suggest that the impairment of TLCO was statistically significantly higher in patients with exacerbation of disease than in remission^[70]. This finding is in accordance with other studies^{[61,65,68-70]} which reported a higher prevalence of impaired TLCO among patients with active IBD disease as compared to patients in remission. In contrast, Douglas et al^[71] reported a reduced gas transfer factor in 16% of 44 patients with IBD but these abnormalities were not related to disease activity. The reduction in gas transfer factor indicates damage to lung parenchyma. The nature of this lung involvement remains debatable. However, some explanations will be discussed in the following section concerning the relationship between IBD and interstitial lung complications.

INTERSTITIAL LUNG COMPLICATIONS

Interstitial lung involvement has been reported to accompany both clinical IBD entities, UC^[72-78] and CD^[79-83]. The interstitial lung infiltrates have been proven histologically to be either pulmonary vasculitis^[76,77,84] or more often granulomatous disease^{[74,79,80,82,83,85,86]}. Treatment with corticosteroids^[75,78] or with appropriate medication such as sulfasalazine or mesalamine for the basic gastrointestinal disease^[74] appeared to be satisfactory for both diseases. Pneumonitis, in contrast, due either to sulphasalazine or mesalamine is a well-recognized adverse drug reaction in these patients^[50,87-95].

    The above observations and the histological simila­rities between CD and sarcoidosis in particular, have led several groups to investigate the number and types of cells recovered by bronchoalveolar lavage (BAL)^[58,59,96]. An increased percentage of alveolar lymphocytes was reported in the study by Wallaert et al^[58] in patients with CD. In the same study, a correlation between BAL differential cell count and PFTs abnormalities, drug treatment or CD site and activity was not reported^[58]. The same group reported an increased level of IgG and IgM in BAL recovered from patients with alveolitis but not in those with normal BAL^[97]. This observation of subclinical alveolitis was confirmed in the study by Bonniere and associates in 22 patients with CD^[59]. In the same study, a significant increase in superoxide anion production by alveolar macrophages related to spontaneous activation and alteration of pulmonary function was observed^[59,98]. Bartholo et al^[99] found lymphocytosis in induced sputum of patients with CD even without pulmonary symptoms. Raj et al^[100] reported a trend for higher lymphocyte counts in the sputum of patients with CD compared with UC. Smiéjan et al^[96] reported lymphocytosis alveolitis in patients with CD but not in patients with other inflammatory bowel disorders including UC. In the same study, an increase in the CD4 lymphocyte subset (increased ratio of CD4/CD8) was found in patients with an active stage of CD similar to patients with sarcoidosis^[96]. Yamaguchi et al^[101] reported increased BAL lymphocytes with an elevated CD4/CD8 ratio and enhanced expression of CD2 antigen in lung T cells in 8 patients with CD. Ussov et al^[102] found a significant increase in the pulmonary vascular granulocyte pool in patients with CD. The meaning of this subclinical alveolitis and alterations in lung parenchyma is unclear. A subclinical inflammatory alveolitis as assessed by BAL cell analysis may be present in asymptomatic patients with immunological systemic disorders and with normal chest X-ray^[103]. The fact that pulmonary involvement is not as common during extrathoracic granulomatosis as CD, whereas subclinical alveolitis is frequent, suggests that the lung possibly downregulates, in some way, alveolar inflammation due to the systemic immune disorder. The alveolitis observed in IBD patients does not necessarily precede the development of pulmonary granulomatosis and fibrosis^[97,103]. Increased pulmonary permeability to diethylenetriaminepenta-acetate radiolabelled with 99m-technetium (^99mTc-DTPA) related to abnormal BAL findings has also been reported in patients with CD^[104]. The reduction in diffusing capacity of the lungs (DLCO) is common and early manifestations of interstitial lung diseases^[64,68,97] and latent lymphocytosis alveolitis could explain, in part, the reduction in DLCO observed in patients with CD^[60].

ATOPY AND IBD

The gastrointestinal tract comes into direct contact with a great variety of foreign substances and under certain conditions these may act as antigens causing allergic reactions^[105]. On the other hand, atopic subjects are possibly susceptible to several inhalants or food allergens^[106], while clinical features of atopic disorders include many organs among them both the pulmonary and gastrointestinal systems. Hippocrates reported that milk could cause gastric upset and urticaria and was probably the first to relate general atopy with gastrointestinal allergy. Hammer et al^[107] found an increased prevalence of all atopic features. Asthma was also documented as being highly prevalent in a large study by Bernstein et al^[108]. Studies on the relation between IBD and atopy are listed in Table 1. Ceyhan et al^[109] reported that allergic symptoms and skin prick test positivity were more common in IBD patients (Table 1). Fireman et al^[110] reported a higher percentage of eosinophils in induced sputum in patients with UC. Several studies have tried to investigate the attractive hypothesis that IBD, in particular UC, may be an allergic response to food^[111,112] especially in individuals susceptible to various allergens. This hypothesis is supported by certain evidence that eosinophils and eosinophil-derived mediators contribute to the histopathology and pathophysiology of IBD^[19,113-116]. Most studies confirmed the observation that atopic features are more frequent in patients with IBD than in the general population^{[114,117-120]} (Table 1). This may be an explanation for the overlap­ping allergic disorders in both the respiratory and gastrointestinal systems. However, the frequency of bronchial hyperresponsiveness was significantly higher in IBD patients than in normal subjects (41% vs 5%), even when non-atopic subjects were considered^[53]. This finding is consistent with the hypothesis that another immune system common to both exists and may be responsible for the inflammation in both systems^[36]. Only one study by Troncone et al^[121] showed that there was no correlation between atopy and IBD.

    Engkilde et al^[122] found an inverse association between a contact allergy and IBD. In this study although there was a chronic contact allergic dermatitis which was considered by the authors to have a Th2 profile, contact allergy has a Th1 profile. Engkilde et al^[122] suggested that this may be due to shared genetic factors, common environmental determinants or skewness of the immune system. Medoff et al^[123] suggested that T cell trafficking takes place in peripheral tissue in allergic asthma. It is suggested that this trafficking may involve several interactions between innate immune cells and T cells^[123]. Several explanations for this phenomenon have been given over the years, however, no definite conclusions have been reached. Hammer et al^[107] suggested a genetic predisposition, Myrelid et al^[124] implicated TNF mast cells and D’Arienzo et al^[125] suggested a Th2 or Th1 helper response. The mechanisms of atopy in IBD merit further investigation.

CONCLUSION

Three patterns of pulmonary involvement have been reported to accompany IBD: (1) airway disease includ­ing large airway stenosis, chronic bronchitis, small airway dysfunction, severe bronchial suppuration and bronchiectasis; (2) parenchymal lung involvement either as subclinical lymphocytic alveolitis or several types of pulmonary infiltrate such as granulomatous bronchiolitis and bronchiolitis obliterans; and (3) a reduction in the diffusing capacity of the lung is a well established abnormality of pulmonary function testing in some patients with IBD.

    We propose that patients suffering from IBD should undergo pulmonary evaluation which should include physical examination, chest X-ray and pulmonary function testing with DLCO measurement. This pulmonary evaluation may be useful in detecting subclinical or clinical pulmonary involvement in IBD patients or as a baseline evaluation. In clinical cases with pulmonary manifestations, inhaled or systemically administered steroids appear to be an effective treatment. With regard to atopy, routine investigations should be considered, at least in patients with IBD who also present with airway dysfunction.

REFERENCES

1      Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996; 334: 841-848   PubMed    DOI

2      Podolsky DK. Inflammatory bowel disease (1). N Engl J Med 1991; 325: 928-937   PubMed

3      Shanahan F. Pathogenesis of ulcerative colitis. Lancet 1993; 342: 407-411   PubMed    DOI

4      Shanahan F. The role of autoantibodies and autoimmunity in chronic inflammatory disorders of the gut. Current Opin Gastroenterol 1992; 8: 988-992   DOI

5      Snook J. Are the inflammatory bowel diseases autoimmune disorders? Gut 1990; 31: 961-963   PubMed    DOI

6      Taylor K, Rotter J, Yang H, Targan S, Shanahan F, Karp L. The genetics of inflammatory bowel disease. Inflammatory bowel disease: from bench to bedside. 2nd edition.Baltimore: Williams & Wilkins, 1993: 21-65

7      Koutroubakis I, Crusius JB, Peña AS. Immunogenetics of cytokines. Relevance for future research on inflammatory bowel disease. Scand J Gastroenterol 1995; 30: 1139-1146   PubMed    DOI

8      Yamamoto-Furusho JK. Genetic factors associated with the development of inflammatory bowel disease. World J Gastroenterol 2007; 13: 5594-5597   PubMed

9      Cope GF, Heatley RV. Cigarette smoking and intestinal defences. Gut 1992; 33: 721-723   PubMed    DOI

10    Potter GK. Effect of smoking on chronic inflammatory bowel disease. J R Soc Health 1995; 115: 194   PubMed    DOI

11    Järnerot G, Lindberg E, Tysk C. Smoking and inflammatory bowel disease. Gastroenterol Hepatol 1995; 18: 507-509   PubMed

12    Batty GM, Wilkins WE, Morris JS. Ulcerative colitis in a husband and wife. Gut 1994; 35: 562-563   PubMed    DOI

13    Koutroubakis I, Manousos ON, Meuwissen SG, Pena AS. Environmental risk factors in inflammatory bowel disease. Hepatogastroenterology 1996; 43: 381-393   PubMed

14    Gardiner KR, Halliday MI, Barclay GR, Milne L, Brown D, Stephens S, Maxwell RJ, Rowlands BJ. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 1995; 36: 897-901   PubMed    DOI

15    Sternberg EM, Chrousos GP, Wilder RL, Gold PW. The stress response and the regulation of inflammatory disease. Ann Intern Med 1992; 117: 854-866   PubMed

16    Singh S, Graff LA, Bernstein CN. Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol 2009; 104: 1298-1313; quiz 1314   PubMed    DOI

17    Russel MG, Stockbrügger RW. Epidemiology of inflam­matory bowel disease: an update. Scand J Gastroenterol 1996; 31: 417-427   PubMed    DOI

18    Hommes DW, Meenan J, de Haas M, ten Kate FJ, von dem Borne AE, Tytgat GN, van Deventer SJ. Soluble Fc gamma receptor III (CD 16) and eicosanoid concentrations in gut lavage fluid from patients with inflammatory bowel disease: reflection of mucosal inflammation. Gut 1996; 38: 564-567   PubMed

19    Walsh RE, Gaginella TS. The eosinophil in inflammatory bowel disease. Scand J Gastroenterol 1991; 26: 1217-1224   PubMed    DOI

20    Liu Z, Yang L, Cui Y, Wang X, Guo C, Huang Z, Kan Q, Liu Z, Liu Y. Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 1133-1144   PubMed

21    Levine JB, Lukawski-Trubish D. Extraintestinal consider­ations in inflammatory bowel disease. Gastroenterol Clin North Am 1995; 24: 633-646   PubMed

22    Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National Cooperative Crohn's Disease Study: extraintestinal mani­festations and perianal complications. Gastroenterology 1979; 77: 914-920   PubMed

23    Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976; 55: 401-412   PubMed

24    Storch I, Sachar D, Katz S. Pulmonary manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2003; 9: 104-115   PubMed    DOI

25    Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006; 12: 4819-4831   PubMed

26    Rankin GB. Extraintestinal and systemic manifestations of inflammatory bowel disease. Med Clin North Am 1990; 74: 39-50   PubMed

27    Danzi JT. Extraintestinal manifestations of idiopathic inflammatory bowel disease. Arch Intern Med 1988; 148: 297-302   PubMed    DOI

28    Podolsky DK. Inflammatory bowel disease (2). N Engl J Med 1991; 325: 1008-1016   PubMed

29    Camus P, Colby TV. The lung in inflammatory bowel disease. Eur Respir J 2000; 15: 5-10   PubMed    DOI

30    Black H, Mendoza M, Murin S. Thoracic manifestations of inflammatory bowel disease. Chest 2007; 131: 524-532   PubMed    DOI

31    Marvisi M. Pulmonary involvement in systemic disorders. Curr Drug Targets Inflamm Allergy 2004; 3: 435   PubMed    DOI

32    Camus P, Piard F, Ashcroft T, Gal AA, Colby TV. The lung in inflammatory bowel disease. Medicine (Baltimore) 1993; 72: 151-183   PubMed    DOI

33    Casey MB, Tazelaar HD, Myers JL, Hunninghake GW, Kakar S, Kalra SX, Ashton R, Colby TV. Noninfectious lung pathology in patients with Crohn's disease. Am J Surg Pathol 2003; 27: 213-219   PubMed

34    Kraft SC, Earle RH, Roesler M, Esterly JR. Unexplained bronchopulmonary disease with inflammatory bowel disease. Arch Intern Med 1976; 136: 454-459   PubMed    DOI

35    Butland RJ, Cole P, Citron KM, Turner-Warwick M. Chronic bronchial suppuration and inflammatory bowel disease. Q J Med 1981; 50: 63-75   PubMed

36    Higenbottam T, Cochrane GM, Clark TJ, Turner D, Millis R, Seymour W. Bronchial disease in ulcerative colitis. Thorax 1980; 35: 581-585   PubMed    DOI

37    Garg K, Lynch DA, Newell JD. Inflammatory airways disease in ulcerative colitis: CT and high-resolution CT features. J Thorac Imaging 1993; 8: 159-163   PubMed

38    Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Fukukita S, Tsutsui K, Imoto I, Suzuki S, Kitagawa T. Bronchopulmonary disease in ulcerative colitis. Intern Med 1992; 31: 1155-1159   PubMed    DOI

39    Spira A, Grossman R, Balter M. Large airway disease associated with inflammatory bowel disease. Chest 1998; 113: 1723-1726   PubMed    DOI

40    Eaton TE, Lambie N, Wells AU. Bronchiectasis following colectomy for Crohn's disease. Thorax 1998; 53: 529-531   PubMed

41    Rickli H, Fretz C, Hoffman M, Walser A, Knoblauch A. Severe inflammatory upper airway stenosis in ulcerative colitis. Eur Respir J 1994; 7: 1899-1902   PubMed    DOI

42    Swinburn CR, Jackson GJ, Cobden I, Ashcroft T, Morritt GN, Corris PA. Bronchiolitis obliterans organising pneumonia in a patient with ulcerative colitis. Thorax 1988; 43: 735-736   PubMed    DOI

43    Wilcox P, Miller R, Miller G, Heath J, Nelems B, Muller N, Ostrow D. Airway involvement in ulcerative colitis. Chest 1987; 92: 18-22   PubMed    DOI

44    Vandenplas O, Casel S, Delos M, Trigaux JP, Melange M, Marchand E. Granulomatous bronchiolitis associated with Crohn's disease. Am J Respir Crit Care Med 1998; 158: 1676-1679   PubMed

45    Iwama T, Higuchi T, Imajo M, Akagawa S, Matsubara O, Mishima Y. Tracheo-bronchitis as a complication of Crohn's disease--a case report. Jpn J Surg 1991; 21: 454-457   PubMed    DOI

46    Shad JA, Sharieff GQ. Tracheobronchitis as an initial presentation of ulcerative colitis. J Clin Gastroenterol 2001; 33: 161-163   PubMed

47    Veloso FT, Rodrigues H, Aguiar MM. Bronchiolitis obliterans in ulcerative colitis. J Clin Gastroenterol 1994; 19: 339-341   PubMed    DOI

48    Kuźniar T, Sleiman C, Brugière O, Groussard O, Mal H, Mellot F, Pariente R, Malolepszy J, Fournier M. Severe tracheobronchial stenosis in a patient with Crohn's disease. Eur Respir J 2000; 15: 209-212   PubMed    DOI

49    Neilly JB, Main AN, McSharry C, Murray J, Russell RI, Moran F. Pulmonary abnormalities in Crohn's disease. Respir Med 1989; 83: 487-491   PubMed    DOI

50    Constantinidis KA. Letter: Eosinophilic pneumonia: an unusual side effect of therapy with salicylazosulfapyridine. Chest 1976; 70: 315-316   PubMed    DOI

51    Ekbom A, Brandt L, Granath F, Löfdahl CG, Egesten A. Increased risk of both ulcerative colitis and Crohn's disease in a population suffering from COPD. Lung 2008; 186: 167-172   PubMed    DOI

52    Tzanakis N, Samiou M, Bouros D, Mouzas J, Kouroumalis E, Siafakas NM. Small airways function in patients with inflammatory bowel disease. Am J Respir Crit Care Med 1998; 157: 382-386   PubMed

53    Louis E, Louis R, Drion V, Bonnet V, Lamproye A, Radermecker M, Belaiche J. Increased frequency of bronchial hyperresponsiveness in patients with inflammatory bowel disease. Allergy 1995; 50: 729-733   PubMed    DOI

54    Lisciandrano D, Ranzi T, Carrassi A, Sardella A, Campanini MC, Velio P, Bianchi PA. Prevalence of oral lesions in inflammatory bowel disease. Am J Gastroenterol 1996; 91: 7-10   PubMed

55    Case records of the Massachusetts General Hospital. Case 29-1967. N Engl J Med 1967; 277: 92-101   PubMed

56    Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-1978. N Engl J Med 1978; 299: 538-544   PubMed

57    Bienenstock J. Cellular communication networks. Impli­cations for our understanding of gastrointestinal physiology. Ann N Y Acad Sci 1992; 664: 1-9   PubMed

58    Wallaert B, Colombel JF, Tonnel AB, Bonniere P, Cortot A, Paris JC, Voisin C. Evidence of lymphocyte alveolitis in Crohn's disease. Chest 1985; 87: 363-367   PubMed    DOI

59    Bonniere P, Wallaert B, Cortot A, Marchandise X, Riou Y, Tonnel AB, Colombel JF, Voisin C, Paris JC. Latent pulmonary involvement in Crohn's disease: biological, functional, bronchoalveolar lavage and scintigraphic studies. Gut 1986; 27: 919-925   PubMed    DOI

60    Munck A, Murciano D, Pariente R, Cezard JP, Navarro J. Latent pulmonary function abnormalities in children with Crohn's disease. Eur Respir J 1995; 8: 377-380   PubMed    DOI

61    Overdahl MC, Julian MW, Weisbrode SE, Davis WB, Dorinsky PM. Paraaminosalicylate blocks that ileal injury induced by phorbol myristate acetate. Am J Respir Crit Care Med 1994; 149: 1640-1647   PubMed

62    Johnson NM, Mee AS, Jewell DP, Clarke SW. Pulmonary function in inflammatory bowel disease. Digestion 1978; 18: 416-418   PubMed    DOI

63    Mohamed-Hussein AA, Mohamed NA, Ibrahim ME. Changes in pulmonary function in patients with ulcerative colitis. Respir Med 2007; 101: 977-982   PubMed

64    Herrlinger KR, Noftz MK, Dalhoff K, Ludwig D, Stange EF, Fellermann K. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am J Gastroenterol 2002; 97: 377-381   PubMed    DOI

65    Heatley RV, Thomas P, Prokipchuk EJ, Gauldie J, Sieniewicz DJ, Bienenstock J. Pulmonary function abnormalities in patients with inflammatory bowel disease. Q J Med 1982; 51: 241-250   PubMed

66    Eade OE, Smith CL, Alexander JR, Whorwell PJ. Pulmonary function in patients with inflammatory bowel disease. Am J Gastroenterol 1980; 73: 154-156   PubMed

67    Sethy PK, Dutta U, Aggrawal AN, Das R, Gulati M, Sinha SK, Singh K. Pulmonary and hematological alterations in idiopathic ulcerative colitis. Indian J Gastroenterol 2003; 22: 176-179   PubMed

68    Marvisi M, Borrello PD, Brianti M, Fornarsari G, Marani G, Guariglia A. Changes in the carbon monoxide diffusing capacity of the lung in ulcerative colitis. Eur Respir J 2000; 16: 965-968   PubMed    DOI

69    Songür N, Songür Y, Tüzün M, Doğan I, Tüzün D, Ensari A, Hekimoglu B. Pulmonary function tests and high-resolution CT in the detection of pulmonary involvement in inflammatory bowel disease. J Clin Gastroenterol 2003; 37: 292-298   PubMed

70    Tzanakis N, Bouros D, Samiou M, Panagou P, Mouzas J, Manousos O, Siafakas N. Lung function in patients with inflammatory bowel disease. Respir Med 1998; 92: 516-522   PubMed    DOI

71    Douglas JG, McDonald CF, Leslie MJ, Gillon J, Crompton GK, McHardy GJ. Respiratory impairment in inflammatory bowel disease: does it vary with disease activity? Respir Med 1989; 83: 389-394   PubMed    DOI

72    Theodoropoulos G, Archimandritis A, Davaris P, Plataris J, Melissinos K. Ulcerative colitis and sarcoidosis: a curious association-report of a case. Dis Colon Rectum 1981; 24: 308-310   PubMed

73    Rubinstein I, Baum GL. Association of ulcerative colitis and sarcoidosis? Chest 1986; 89: 618-619   PubMed    DOI

74    Mazer BD, Eigen H, Gelfand EW, Brugman SM. Remission of interstitial lung disease following therapy of associated ulcerative colitis. Pediatr Pulmonol 1993; 15: 55-59   PubMed    DOI

75    McCulloch AJ, McEvoy A, Jackson JD, Jarvis EH. Severe steroid responsive pneumonitis associated with pyoderma gangrenosum and ulcerative colitis. Thorax 1985; 40: 314-315   PubMed    DOI

76    Isenberg JI, Goldstein H, Korn AR, Ozeran RS, Rosen V. Pulmonary vasculitis--an uncommon complication of ulcerative colitis. Report of a case. N Engl J Med 1968; 279: 1376-1377   PubMed

77    Forrest JA, Shearman DJ. Pulmonary vasculitis and ulcerative colitis. Am J Dig Dis 1975; 20: 482-486   PubMed    DOI

78    Balestra DJ, Balestra ST, Wasson JH. Ulcerative colitis and steroid-responsive, diffuse interstitial lung disease. A trial of N = 1. JAMA 1988; 260: 62-64   PubMed    DOI

79    Beer TW, Edwards CW. Pulmonary nodules due to reactive systemic amyloidosis (AA) in Crohn's disease. Thorax 1993; 48: 1287-1288   PubMed    DOI

80    Puntis JW, Tarlow MJ, Raafat F, Booth IW. Crohn's disease of the lung. Arch Dis Child 1990; 65: 1270-1271   PubMed    DOI

81    Calder CJ, Lacy D, Raafat F, Weller PH, Booth IW. Crohn's disease with pulmonary involvement in a 3 year old boy. Gut 1993; 34: 1636-1638   PubMed    DOI

82    Le Roux P, Boulloche J, Briquet MT, Guyonnaud CD, Le Luyer B. [Respiratory manifestation of Crohn's disease. Apropos of a case in an adolescent] Rev Mal Respir 1995; 12: 59-61   PubMed

83    Kayser K, Probst F, Gabius HJ, Müller KM. Are there characteristic alterations in lung tissue associated with Crohn's disease? Pathol Res Pract 1990; 186: 485-490   PubMed

84    Collins WJ, Bendig DW, Taylor WF. Pulmonary vasculitis complicating childhood ulcerative colitis. Gastroenterology 1979; 77: 1091-1093   PubMed

85    McKee AL, Rajapaksa A, Kalish PE, Pitchumoni CS. Severe interstitial pulmonary fibrosis in a patient with chronic ulcerative colitis. Am J Gastroenterol 1983; 78: 86-89   PubMed

86    Meadway J. Ulcerative colitis, colitic spondylitis and asso­ciated apical pulmonary fibrosis. Proc R Soc Med 1974; 67: 324-325   PubMed

87    Jones GR, Malone DN. Sulphasalazine induced lung disease. Thorax 1972; 27: 713-717   PubMed    DOI

88    Williams T, Eidus L, Thomas P. Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy. Chest 1982; 81: 766-768   PubMed    DOI

89    Davies D, MacFarlane A. Fibrosing alveolitis and treatment with sulphasalazine. Gut 1974; 15: 185-188   PubMed    DOI

90    Yaffe BH, Korelitz BI. Sulfasalazine pneumonitis. Am J Gastroenterol 1983; 78: 493-494   PubMed

91    Reinoso MA, Schroeder KW, Pisani RJ. Lung disease associated with orally administered mesalamine for ulcerative colitis. Chest 1992; 101: 1469-1471   PubMed    DOI

92    Welte T, Hamm H, Fabel H. Mesalazine alveolitis. Lancet 1991; 338: 1273   PubMed    DOI

93    Sebastian Domingo JJ, Ventura A, Pérez de Ayala V, Castellanos D. Hypersensitivity pneumonitis by sulphasa­lazine. Allergy 1989; 44: 522   PubMed

94    Sviri S, Gafanovich I, Kramer MR, Tsvang E, Ben-Chetrit E. Mesalamine-induced hypersensitivity pneumonitis. A case report and review of the literature. J Clin Gastroenterol 1997; 24: 34-36   PubMed

95    Guslandi M. Respiratory distress during mesalamine therapy. Dig Dis Sci 1999; 44: 48-49   PubMed

96    Smiéjan JM, Cosnes J, Chollet-Martin S, Soler P, Basset FM, Le Quintrec Y, Hance AJ. Sarcoid-like lymphocytosis of the lower respiratory tract in patients with active Crohn's disease. Ann Intern Med 1986; 104: 17-21   PubMed

97    Wallaert B, Dugas M, Dansin E, Perez T, Marquette CH, Ramon P, Tonnel AB, Voisin C. Subclinical alveolitis in immunological systemic disorders. Transition between health and disease? Eur Respir J 1990; 3: 1206-1216   PubMed

98    Wallaert B, Aerts C, Bonniere P, Cortot A, Tonnel AB, Paris JC, Voisin C. Superoxide anion generation by alveolar macrophages in Crohn's disease. N Engl J Med 1985; 312: 444-445   PubMed

99    Bartholo RM, Zaltman C, Elia C, Cardoso AP, Flores V, Lago P, Cassabian L, Dorileo FC, Lapa-e-Silva JR. Bronchial hyperresponsiveness and analysis of induced sputum cells in Crohn's disease. Braz J Med Biol Res 2005; 38: 197-203   PubMed    DOI

100  Raj AA, Birring SS, Green R, Grant A, de Caestecker J, Pavord ID. Prevalence of inflammatory bowel disease in patients with airways disease. Respir Med 2008; 102: 780-785   PubMed    DOI

101  Yamaguchi E, Okazaki N, Itoh A, Furuya K, Abe S, Kawakami Y. Enhanced expression of CD2 antigen on lung T cells. Am Rev Respir Dis 1991; 143: 829-833   PubMed

102  Ussov WY, Peters AM, Glass DM, Gunasekera RD, Hughes JM. Measurement of the pulmonary vascular granulocyte pool. J Appl Physiol 1995; 78: 1388-1395   PubMed

103  Wallaert B. Subclinical alveolitis in immunologic systemic disorders. Lung 1990; 168 Suppl: 974-983   PubMed    DOI

104  Adenis A, Colombel JF, Lecouffe P, Wallaert B, Hecquet B, Marchandise X, Cortot A. Increased pulmonary and intestinal permeability in Crohn's disease. Gut 1992; 33: 678-682   PubMed    DOI

105  Zanjanian MH. The intestine in allergic diseases. Ann Allergy 1976; 37: 208-218   PubMed

106  Siegel J. Inflammatory bowel disease: another possible effect of the allergic diathesis. Ann Allergy 1981; 47: 92-94   PubMed

107  Hammer B, Ashurst P, Naish J. Diseases associated with ulcerative colitis and Crohn's disease. Gut 1968; 9: 17-21   PubMed    DOI

108  Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005; 129: 827-836   PubMed    DOI

109  Ceyhan BB, Karakurt S, Cevik H, Sungur M. Bronchial hyperreactivity and allergic status in inflammatory bowel disease. Respiration 2003; 70: 60-66   PubMed    DOI

110  Fireman E, Masarwy F, Groisman G, Shtark M, Kopelman Y, Kivity S, Fireman Z. Induced sputum eosinophilia in ulcerative colitis patients: the lung as a mirror image of intestine? Respir Med 2009; 103: 1025-1032   PubMed    DOI

111  Smart HL, Mayberry JF. Atopy, food and ulcerative colitis. Hepatogastroenterology 1986; 33: 47-48   PubMed

112  Glassman MS, Newman LJ, Berezin S, Gryboski JD. Cow's milk protein sensitivity during infancy in patients with inflammatory bowel disease. Am J Gastroenterol 1990; 85: 838-840   PubMed

113  Choy MY, Walker-Smith JA, Williams CB, MacDonald TT. Activated eosinophils in chronic inflammatory bowel disease. Lancet 1990; 336: 126-127   PubMed    DOI

114  Levo Y, Shalit M, Wollner S, Fich A. Serum IgE levels in patients with inflammatory bowel disease. Ann Allergy 1986; 56: 85-87   PubMed

115  Berstad A, Børkje B, Riedel B, Elsayed S, Berstad A. Increased fecal eosinophil cationic protein in inflammatory bowel disease. Hepatogastroenterology 1993; 40: 276-278   PubMed

116  Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoat­tractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996; 2: 449-456   PubMed    DOI

117  Pugh SM, Rhodes J, Mayberry JF, Roberts DL, Heatley RV, Newcombe RG. Atopic disease in ulcerative colitis and Crohn's disease. Clin Allergy 1979; 9: 221-223   PubMed    DOI

118  Roberts DL, Rhodes J, Heatley RV, Newcombe RG. Atopic features in ulcerative colitis. Lancet 1978; 1: 1262   PubMed    DOI

119  Mee AS, Brown D, Jewell DP. Atopy in inflammatory bowel disease. Scand J Gastroenterol 1979; 14: 743-746   PubMed

120  Jewell DP, Truelove SC. Reaginic hypersensitivity in ulcerative colitis. Gut 1972; 13: 903-906   PubMed    DOI

121  Troncone R, Merrett TG, Ferguson A. Prevalence of atopy is unrelated to presence of inflammatory bowel disease. Clin Allergy 1988; 18: 111-117   PubMed    DOI

122  Engkilde K, Menné T, Johansen JD. Inflammatory bowel disease in relation to contact allergy: a patient-based study. Scand J Gastroenterol 2007; 42: 572-576   PubMed    DOI

123  Medoff BD, Thomas SY, Luster AD. T cell trafficking in allergic asthma: the ins and outs. Annu Rev Immunol 2008; 26: 205-232   PubMed    DOI

124  Myrelid P, Dufmats M, Lilja I, Grinn C, Lannerstad O, Sjödahl R. Atopic manifestations are more common in patients with Crohn disease than in the general population. Scand J Gastroenterol 2004; 39: 731-736   PubMed

125  D'Arienzo A, Manguso F, Astarita C, D'Armiento FP, Scarpa R, Gargano D, Scaglione G, Vicinanza G, Bennato R, Mazzacca G. Allergy and mucosal eosinophil infiltrate in ulcerative colitis. Scand J Gastroenterol 2000; 35: 624-631   PubMed

S- Editor  Wang YR    L- Editor  Webster JR    E- Editor  Lin YP

Reviews	Add
more>>